Background Advances in systemic therapy for advanced hepatocellular carcinoma (HCC) have fuelled a growing interest in ...
Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid cancers, portending poor patient outcomes ...
Background Hospitalisations represent major clinical events in cirrhosis, yet prediction based on clinical variables alone ...
Eosinophilic gastritis (EoG) is a rare, chronic disease characterised by pathological eosinophilia of the stomach and ...
Background Engineered bacterial therapeutics represent a promising strategy for sustained intestinal delivery of therapeutic ...
Background Programmed death ligand 1 (PD-L1) blockade offers new therapeutic options for oesophageal squamous cell carcinoma ...
Background Translating microbiome correlations into robust predictive features for complex gut disorders remains elusive, ...
The recent conditional US Food and Drug Administration (FDA) approval of two therapies, resmetirom (Rezdiffra) and semaglutide (Wegovy), marks the first time clinicians have pharmacological therapy ...
Recent work in Gut has highlighted multi-kingdom interactions between gut bacteria and bacteriophage (‘phage’) as contributors to Crohn’s disease.1 Whether similar alterations characterise colorectal ...
A recent systematic review and meta-analysis by Shiha et al, synthesising 25 studies and nearly 50 000 participants, estimated that approximately 1 in 10 individuals self-reported gluten or ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous condition where overlapping cardiometabolic risk factors challenge accurate prognostic prediction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results